1 March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25:544-551 [DOI via Crossref] [Pubmed] |
|
2 Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91:4237-4245. [DOI via Crossref] [Pubmed] |
|
3 Harwood K, Vuguin P, DiMartino-Nardi J. Current ap-proaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res. 2007; 68(5):209-217. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
4 American Heart Association. Heart disease and stroke statistics—2004 Update. Dallas, TX, USA: American Heart Association, 2003 |
|
5 Demirbag R, Yilmaz R, Gur M, et al. Lymphocyte DNA damage in patients with acute coronary syndrome and its relationship with severity of acute coronary syn-drome. Mutat. Res. 2005; 578:298-307. [DOI via Crossref] [Pubmed] |
|
6 Guven M, Guven GS, Oz E, Ozaydin A, et al. DNA repair gene XRCC1 and XPD polymorphisms and their association with coronary artery disease risks and micronucleus frequency. Heart Vessels 2007; 22:355-360 [DOI via Crossref] [Pubmed] |
|
7 Simon AS, Roy DD, Jayapal V, Vijayakumar T. Somatic DNA damages in cardiovascular autonomic neuropathy. Indian J Clin Biochem. 2011; 26(1):50-56. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|
8 Andreassi MG, Barale R, Iozzo P, Picano E. The association of micronucleus frequency with obesity, diabetes and cardiovascular disease. Mutagenesis 2011; 26 (1):77-83. [DOI via Crossref] [Pubmed] |
|
9 Svendsen PF, Nilas L, Nørgaard K, Madsbad S. Polycystic ovary syndrome. New patho-physiological discoveries-therapeutic consequences. Ugeskr Laeger. 2005; 167(34):3147-3151. [Pubmed] |
|
10 Hsu TC, Cherry LM, Saman NAO. Differential Mutagen sensitivity in cultured lymphocytes of normal individuals and cancer patients. Cancer Genet. Cytogenet 1985; 17:307-313. [DOI via Crossref] |
|
11 Carmina E. Cardiovascular risk and events in polycystic ovary syndrome. Climateric 2009; 12 (Suppl 1):22–25. [DOI via Crossref] [Pubmed] |
|
12 Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607–613 [DOI via Crossref] |
|
13 Essah PA, Nestler JE, Carmina E. Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome. J Endocrinol Invest 2008; 31:35–41. [DOI via Crossref] [Pubmed] |
|
14 Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008; 93:470–476. [DOI via Crossref] [Pubmed] |
|
15 Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24:2286–2292. [DOI via Crossref] [Pubmed] |
|
16 Simon AS, Roy DD, Jayapal V, Vijayakumar T. Biochemical and genetic studies on cardiometabolic syndrome. Indian J Clin Biochem. 2010; 25:164-168. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] |
|